Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

University of British Columbia: Clinical Trials & FDA Approval Profile

University of British Columbia (Global / Institutional) sponsors 42 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 14 active protocols (7 recruiting now), 6 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)16.7%
Median Closed Enrollment vs National (145 pts)52 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for University of British Columbia
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)42
Active Pipeline (Recruiting Now)14 (7)
Completed vs Stopped Early6 / 7 (16.7%)
Median Closed Actual Enrollment52 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With University of British Columbia
Hospital Research SiteLocationShared Protocols
Vancouver General HospitalVancouver, British Columbia7
Sunnybrook Health Sciences CentreToronto, Ontario3
UC Davis Comprehensive Cancer CenterSacramento, CA2

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by University of British Columbia
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT04812366Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate CancerPhase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the University of British Columbia Interactive Dossier, benchmark peers in Neurology, Psychiatry, and Pain, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI